drugset / Trial / NCT01455025
Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
Phase 1
Terminated
11 enrolled
French Innovative Leukemia Organisation
Acute Leukemia French Association · collabGenzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, dose escalation study of Plerixafor in combination with granulocyte-colony stimulating factor , Daunorubicin and Cytarabine in adults patients with relapsed acute myeloid leukemia .
Timeline
- Start
- 2012-01
- Primary completion
- 2015-03
- Completion
- 2015-08
Outcome
Outcome not reported
Stopped (Enrollment): “no recruitment on time”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | 240 ug/kg | Intravenous |
| Subject | Plerixafor | Small molecule | 480 ug/kg | Intravenous |
| Background | Cytarabine | Small molecule | 500 mg/m2 | — |
| Background | Cytarabine | Small molecule | 1000 mg/m2 | — |
| Background | Cytarabine | Small molecule | 3000 mg/m2 | — |
| Background | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |